Chronic Heart Failure Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Chronic Heart Failure Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major chronic heart failure markets reached a value of US$ 6.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 18.5 Billion by 2034, exhibiting a growth rate (CAGR) of 9.78% during 2024-2034.

The chronic heart failure market has been comprehensively analyzed in IMARC's new report titled "Chronic Heart Failure Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic heart failure (CHF), also known as congestive heart failure, is a progressive condition in which the heart is unable to pump enough blood to meet the body's needs. Some of the common symptoms indicative of the ailment are irregular heartbeat, fatigue, shortness of breath, chest pain, nausea, swelling in the legs, ankles, and feet, coughing, etc. The diagnosis of chronic heart failure typically involves a comprehensive evaluation that includes a medical history, physical examination, and various tests. The physical examination is performed to measure the vital signs and evaluate the heart and lung functions. Some of the laboratory investigations used to diagnose CHF include blood tests, electrocardiogram (ECG), chest X-ray, echocardiogram, and cardiac catheterization. Blood tests are carried out to identify any underlying health problems that may contribute to heart failure, such as anemia or kidney problems. Additionally, an ECG can help detect abnormalities in the heart's electrical activity, while an echocardiogram provides a detailed view of the heart's structure and function.

The increasing prevalence of coronary artery ailments and heart valve disorders is primarily driving the chronic heart failure market. In addition to this, the rising incidence of several CHF-associated prominent co-morbidities, such as obesity, diabetes, pulmonary diseases, hypertension, etc., is creating a positive outlook for the market. Furthermore, the expanding geriatric population, who are more susceptible to developing cardiovascular diseases, is also bolstering the market growth. Apart from this, the widespread adoption of device-based therapies, including cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillators (ICDs), which utilize implantable devices to improve the heart's pumping function, is acting as a significant growth-inducing factor. Moreover, the increasing utilization of medications, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), to reduce fluid buildup and relieve symptoms of chronic heart failure, including shortness of breath and fatigue, is further propelling the market. Additionally, several technological advancements, such as the introduction of cardiac mapping devices for identifying the cause of CHF, such as arrhythmias, structural heart defects, or ischemia, are also expected to drive the chronic heart failure market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the chronic heart failure market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for chronic heart failure and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic heart failure market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic heart failure market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic heart failure market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chronic heart failure marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the chronic heart failure market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chronic heart failure market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chronic heart failure market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of chronic heart failure across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic heart failure by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic heart failure by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with chronic heart failure across the seven major markets?
What is the size of the chronic heart failure patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of chronic heart failure?
What will be the growth rate of patients across the seven major markets?

Chronic Heart Failure: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chronic heart failure drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic heart failure market?
What are the key regulatory events related to the chronic heart failure market?
What is the structure of clinical trial landscape by status related to the chronic heart failure market?
What is the structure of clinical trial landscape by phase related to the chronic heart failure market?
What is the structure of clinical trial landscape by route of administration related to the chronic heart failure market? Show more